VAN WIJMEERSCH, Bart

Email Alert RSS Feed

Profile

Full Name
VAN WIJMEERSCH, Bart
Email
bart.vanwijmeersch@uhasselt.be
 
Loading... 5 0 5 0 false
Loading... 6 0 5 0 false

Publications

Refined By:
Author:  Oreja-Guevara, C.
Author:  McCombe, P.

Results 1-5 of 5 (Search time: 0.003 seconds).

Issue DateTitleContributor(s)TypeCat.
12020Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)Hartung, H-P; Comi, G.; Arnold, D. L.; Boyko, A. N.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, BartJournal ContributionM
22019Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study)Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H. -P.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, BartJournal ContributionM
32019Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)McCombe, P.; Comi, G.; Arnold, D. L.; Boyko, A. N.; Hartung, H-P; Havrdova, E. K.; Inshasi, J. S.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, BartJournal ContributionM
42019Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progressionDE BROUWER, Edward; PEETERS, Liesbet; BECKER, Thijs; Altintas, A.; Soysal, A.; VAN WIJMEERSCH, Bart; Boz, C.; Oreja-Guevara, C.; Gobbi, C.; Solaro, C.; Ramo, C.; Spitaleri, D. L.; Maimone, D.; Aguera-Morales, E.; Cartechini, E.; Butler, E.; Havrdova, E.; Patti, F.; Granella, F.; Grand'Maison, F.; Moore, F.; Verheul, F.; Luliano, G.; Butzkueven, H.; Lechner-Scott, J.; Kuhle, J.; Sanchez Menoyo, J. L.; Rojas, J. I.; Prevost, J.; Onofrj, M.; Rio, M. E.; Sa, M. J.; Saladino, M. L.; Slee, M.; Barnett, M.; Terzi, M.; Deri, N.; McCombe, P.; Sola, P.; Duquette, P.; Grammond, P.; Ampapa, R.; Alroughani, R.; Hupperts, R.; Turkoglu, R.; Gouider, R.; Fernandez Bolanos, R.; Bergamaschi, R.; Kalincik, T.; Moreau, Y.Journal ContributionM
52016Durable improvement in clinical outcomes in treatmentnaive patients with relapsing-remitting multiple sclerosis who switched from SC IFNB-1a to alemtuzumab (care-MS I extension study 4-year follow-up)Oreja-Guevara, C.; Alroughani, R.; Brassat, D.; Boyko, A. N.; McCombe, P.; Steingo, B.; VAN WIJMEERSCH, Bart; Margolin, D. H.; Thangavelu, K.; Rodriguez, C. E.; Vermersch, P.Journal ContributionM